EPISODE · Dec 16, 2022 · 11 MIN
MPR Weekly Dose 141 — Guidance for Influenza Treatment; Panel Vote on Omecamtiv Mecarbil; Tecentriq Approval; Flu and COVID Combo Vax; Certain COVD Tests Recalled
from MPR Weekly Dose
Interim guidance for influenza treatment with limited oseltamivir; FDA panel vote on omecamtiv mecarbil; Tecentriq gains new indication; Potential combo COVID-19 and influenza vaccine; Detect COVID-19 tests recalled.
Embed this episode
Ready to play
MPR Weekly Dose 141 — Guidance for Influenza Treatment; Panel Vote on Omecamtiv Mecarbil; Tecentriq Approval; Flu and COVID Combo Vax; Certain COVD Tests Recalled
0:00
11:55
1×
No transcript for this episode yet
Similar Episodes
No similar episodes found.
Similar Podcasts
No similar podcasts found.
Frequently Asked Questions
How long is this episode of MPR Weekly Dose?
This episode is 11 minutes long.
When was this MPR Weekly Dose episode published?
This episode was published on December 16, 2022.
Can I download this MPR Weekly Dose episode?
Yes. Use the download control on the episode player to save the publisher-provided media file.
URL copied to clipboard!